AzTrials
AzTrials

ObesityWeGoRealNCT07081178

A Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real-World Clinical Practice in Germany (WeGo Real Germany).

An observational study of Obesity, run by Novo Nordisk A/S at 1 site in Germany.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

Participants will be treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician for the management of obesity. The purpose of this study is to collect data on the effect of Semaglutide under everyday conditions in participants. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Obesity
What is being tested?
Semaglutide
Type of treatment
Injection or infusion
How many people
100 participants
Where
1 siteGermany
Study dates
8 Aug 2025to 18 Dec 2025
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Adult, Older adult

Study population: Two groups of participants are planned to be included, one Group (A) with those initiating semaglutide adjunct with lifestyle modification, and the other Group (B) with those only with lifestyle modification.

Common inclusion criteria for Group A and Group B:

  1. Male or female, age above or equal to 18 years at the time signing informed consent.
  2. Body mass index (BMI) more than or equal to (≥) 30 kilogram per meter square (kg/m^2) with at least one of the following diagnosed obesity-related comorbidities: arterial hypertension, pre-diabetes, Obstructive Sleep Apnea (OSA) or coronary heart disease, chronic heart failure, or BMI ≥35 kg/m^2.
  3. History of at least one self-reported unsuccessful attempt to lose weight.
  4. Capable of completing informed consent.

Additional inclusion criteria for Group A:

  1. The decision to initiate treatment with commercially available Wegovy has been made by the participant and the treating physician before and independently from the decision to include the participant in this study.
  2. Initiation of treatment is not modified in any case due to participant's participation in the study.

Common exclusion criteria for Group A and Group B:

  1. Previous participation in this study (participation is defined as having given informed consent in this study)
  2. Treatment with an investigational drug within 30 days prior to enrolment into the study.
  3. Participant has had a prior serious allergic reaction to semaglutide or any of the ingredients in Wegovy.
  4. Women with pregnancy or breast-feeding.
  5. Women of childbearing potential and not using an adequate contraceptive method.
  6. Men and women in their pregnancy attempts.
  7. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
  8. History of any Glucagon-like peptide-1 (GLP-1) treatment within 180 days.
  9. History of type 1 or type 2 diabetes mellitus.

Trial locations and contacts

1 site in 1 country.

Germany1 site

  • Medizinisches Versorgungszentrum Am Bahnhof Spandau GbR

    Berlin, 13597

Other trials in Germany

About this study

Official title: A Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real-World Clinical Practice in Germany Non-interventional.

Participants will be treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician for the management of obesity. The purpose of this study is to collect data on the effect of Semaglutide under everyday conditions in participants. Participants and doctor had already decided that they will get semaglutide prescribed by doctor, independently of patient's participation in this study. The study will last for 12 months.

Conditions
Obesity
Being tested
Semaglutide
Medical subject headings
Obesity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • SemaglutideDrug

    Semaglutide injection will be self-administered once weekly subcutaneously at any time of the day with or without meals.

Study groups in NCT07081178
Study groupRoleWhat they receive
Group AParticipants will be treated with commercially available semaglutide along with lifestyle modification in the routine clinical practice.
Receives: Drug: Semaglutide
Group BParticipants with lifestyle modification in the routine clinical practice will be included.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in relative body weight

    Percentage (%)

    Measured: From baseline to month 6 and month 9

Secondary outcomes (19)

  1. Change in relative body weight

    Percentage (%)

    Measured: From baseline to month 3 and 12

  2. Change in body weight

    Kilogram (Kg)

    Measured: from baseline to month 3, month 6, month 9 and month 12

  3. Change in Haemoglobin A1c (HbA1c)

    millimoles per mole (mmol/mol)

    Measured: from baseline to month 3, month 6, month 9 and month 12

  4. Change in fasting plasma glucose (FPG)

    milligram per deciliter (mg/dL)

    Measured: from baseline to month 3, month 6, month 9 and month 12

  5. Change in total cholesterol

    mg/dL

    Measured: from baseline to month 3, month 6, month 9 and month 12

  6. Change in high density lipoprotein (HDL)

    mg/dL

    Measured: from baseline to month 3, month 6, month 9 and month 12

  7. Change in low density lipoprotein (LDL)

    mg/dL

    Measured: from baseline to month 3, month 6, month 9 and month 12

  8. Change in very low density lipoprotein (VLDL)

    mg/dL

    Measured: from baseline to month 3, month 6, month 9 and month 12

  9. Change in lipoprotein A [Lp(a)]

    mg/dL

    Measured: from baseline to month 3, month 6, month 9 and month 12

  10. Change in triglycerides

    mg/dL

    Measured: from baseline to month 3, month 6, month 9 and month 12

  11. Change in estimated glomerular filtration rate (eGFR) eGFR

    milliliters per minute per 1.73 square meters (mL/min/1.73m²)

    Measured: from baseline to month 3, month 6, month 9 and month 12

  12. Change in waist circumference

    Centimeter (cm)

    Measured: from baseline to month 3, month 6, month 9 and month 12

  13. Change in systolic blood pressure (SBP)

    millimeters of mercury (mmHg)

    Measured: from baseline to month 3, month 6, month 9 and month 12

  14. Change in diastolic blood pressure (DBP)

    mmHg

    Measured: from baseline to month 3, month 6, month 9 and month 12

  15. Change in C-reactive protein (CRP) or high-sensitivity C-reactive protein (hs-CRP)

    milligrams per liter (mg/L)

    Measured: from baseline to month 3, month 6, month 9 and month 12

  16. Change in platelet count

    number of platelets per liter (10^9/L)

    Measured: from baseline to month 3, month 6, month 9 and month 12

  17. Change in gamma-glutamyl transferase (GGT)

    unit per liter (U/L)

    Measured: from baseline to month 3, month 6, month 9 and month 12

  18. Change in alanine aminotransferase/serum glutamic-pyruvic transaminase (ALT/GPT)

    units per liter (U/L)

    Measured: from baseline to month 3, month 6, month 9 and month 12

  19. Change in aspartate aminotransferase/serum glutamic-oxaloacetic transaminase (AST/GOT)

    units per liter (U/L)

    Measured: from baseline to month 3, month 6, month 9 and month 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Jul 2025
  2. Study start8 Aug 2025
  3. Primary completion18 Dec 2025
  4. Study completion18 Dec 2025

Why it stopped: The study was cancelled prematurely due to lack of patients.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
100 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07081178
Sponsor's protocol ID
NN9536-8332
Other IDs
U1111-1314-8335
Acronym
WeGoReal
Status last verified
Apr 2026
First submitted
15 Jul 2025
Last updated
27 Apr 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Questions about this trial

What is this clinical trial studying?

An observational study of Obesity, run by Novo Nordisk A/S at 1 site in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 27 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: The study was cancelled prematurely due to lack of patients.). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in relative body weight (time frame: From baseline to month 6 and month 9). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07081178.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Apr 2026; AzTrials last refreshed its copy on 6 Nov 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in